TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17986493

Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy (CRT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no CRT)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: CRT (in subgroup with QRS interval of 120 msec or more)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: CRT (in subgroup with QRS interval of less than 120 msec)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 172
Study: 16321612

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (200 microg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (50 microg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (100 microg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (50, 100, 200 microg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 12581507

Group type: EXPERIMENTAL
Intervention: BDP 200 microg bid via HFA-134a
Number of subjects: 172

Group type: COMPARATOR
Intervention: BDP 200 microg bid via CFC
Number of subjects: 172
Study: 9833072

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization technique (FISH)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Chromosomal abnormalities in recurrent meningiomas
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Histopathological and cytogenetic correlations
Number of subjects: 189
Study: 8065789

Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia (PCA) with 0.125% plain bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion system with 0.125% plain bupivacaine
Number of subjects: 60
Study: 2903604

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg kg‐1
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 44
Study: 31645442

Group type: EXPERIMENTAL
Intervention: NZ8123-HPV16-optiE7 vaccine (5 × 109 CFU/mL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NZ8123-HPV16-optiE7 vaccine (1 × 1010 CFU/mL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NZ8123-HPV16-optiE7 vaccine (1 × 109 CFU/mL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 28620764

Group type: EXPERIMENTAL
Intervention: Bullying (frequently and upset)
Number of subjects: 6667

Group type: EXPERIMENTAL
Intervention: Antisocial/aggressive behavior (measured by ESYTC scale)
Number of subjects: 6667
Study: 28882405

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23625906

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (A, C, E and selenium) for 1 month
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not exposed to solvents)
Number of subjects: 39
Study: 24395985

Group type: EXPERIMENTAL
Intervention: Personal digital assistant-delivered communication intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 21178606

Group type: EXPERIMENTAL
Intervention: Oblique fluoroscopic stellate block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anterior paratracheal stellate block
Number of subjects: 50
Study: 18485485

Group type: EXPERIMENTAL
Intervention: Fish oil (omega-3 fatty acids)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Mineral oil (placebo)
Number of subjects: 31
Study: 16756780

Group type: EXPERIMENTAL
Intervention: Hydrostatic membrane sweeping (group-B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Foley's catheter ballooning (group-A)
Number of subjects: 50
Study: 14603951

Group type: EXPERIMENTAL
Intervention: Leukoreduced red cells/fresh frozen plasma using a high efficiency filter at the bedside
Number of subjects: 87

Group type: COMPARATOR
Intervention: Buffycoat-depleted red cells transfused through an aggregate filter
Number of subjects: 87
Study: 11072157

Group type: EXPERIMENTAL
Intervention: Preoperative chemo-radiation (4760 cGy to primary and lymph nodes with concurrent chemotherapy: cisplatin/5-FU)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Preoperative chemo-radiation
Number of subjects: 46
Study: 8650989

Group type: COMPARATOR
Intervention: High performance weight lifters
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sports-boxers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tour de France bikers
Number of subjects: 40
Study: 1547683

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pork insulin
Number of subjects: 10
Study: 3884408

Group type: EXPERIMENTAL
Intervention: Lormetazepam (oral drops)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31703302

Group type: EXPERIMENTAL
Intervention: Psycho-social services (six sessions)
Number of subjects: 248
Study: 29870596

Group type: EXPERIMENTAL
Intervention: Mirogabalin with Tramadol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin with Ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin with Lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin with Zolpidem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirogabalin alone
Number of subjects: 0
Study: 27142873

Group type: EXPERIMENTAL
Intervention: INCA® device feedback and inhaler technique training
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inhaler technique training (comparator group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 75
Study: 23912798

Group type: EXPERIMENTAL
Intervention: MTX + IFX
Number of subjects: 112

Group type: COMPARATOR
Intervention: MTX + intravenous steroid
Number of subjects: 112
Study: 22982023

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment for 30 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo after stopping ICS treatment for 24 months
Number of subjects: 110
Study: 20381890

Group type: EXPERIMENTAL
Intervention: Self-administered intervention to assist patients in formulating plans for self-monitoring of blood glucose (SMBG)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control groups (three control groups used to control for testing effects)
Number of subjects: 402
Study: 18442341

Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 39
Study: 15990571

Group type: EXPERIMENTAL
Intervention: 3TC/ddI/EFV
Number of subjects: 77

Group type: COMPARATOR
Intervention: TDF/ddI/EFV
Number of subjects: 77
Study: 11889577

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (vitamin E 500 mg/day, beta-carotene 30 mg/day, vitamin C 1 g/day for last 15 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10071350

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Original formulation of cyclosporine
Number of subjects: 9
Study: 7675951

Group type: EXPERIMENTAL
Intervention: Caffeine 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2286708

Group type: EXPERIMENTAL
Intervention: Fluphenazine (10-30 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Amobarbital sodium for agitation
Number of subjects: 86
Study: 7434788

Group type: EXPERIMENTAL
Intervention: Sulindac 200-400 mg/day for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg in 10 healthy volunteers
Number of subjects: 20
Study: 30707090

Group type: EXPERIMENTAL
Intervention: Explosive training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 30
Study: 27718637

Group type: EXPERIMENTAL
Intervention: New L-T4 formulation (600 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current L-T4 formulation (600 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-T4 tablets (50 μg, 100 μg, 200 μg)
Number of subjects: 0
Study: 25284802

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 360

Group type: COMPARATOR
Intervention: RFA
Number of subjects: 360
Study: 23659489

Group type: EXPERIMENTAL
Intervention: Standardized heat stimulus applied to the forearm
Number of subjects: 75
Study: 21860291

Group type: EXPERIMENTAL
Intervention: Seven packs of OCPs
Number of subjects: 700

Group type: COMPARATOR
Intervention: Three packs of OCPs
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Seven packs of OCPs (younger than 18 years)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Three packs of OCPs (younger than 18 years)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Seven packs of OCPs (18 years and older)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Three packs of OCPs (18 years and older)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Prescription for refills
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Packs of OCPs
Number of subjects: 700
Study: 19901655

Group type: EXPERIMENTAL
Intervention: Coagulopathic patients (abnormal laboratory tests)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Noncoagulopathic patients (normal laboratory tests)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Abnormal international normalized ratio (INR)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Abnormal platelet count (PLT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Head Abbreviated Injury Scale (AIS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Head AIS (multiple logistic regression)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PLT (multiple logistic regression)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All patients with abnormal partial thromboplastin time
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ICH progression
Number of subjects: 72
Study: 16427057

Group type: EXPERIMENTAL
Intervention: Nurse-directed protocolised-weaning
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual doctor-led practice (Control)
Number of subjects: 140
Study: 15549369

Group type: EXPERIMENTAL
Intervention: Hot treatment (immersion in hot water at 43 degrees C for 16.0 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hot treatment
Number of subjects: 7
Study: 11572325

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and oxandrolone therapy
Number of subjects: 0
Study: 9260058

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autotransplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive therapy (bisphosphonates and erythropoietin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic transplantation
Number of subjects: 0
Study: 8485269

Group type: COMPARATOR
Intervention: MaxEPA
Number of subjects: 43

Group type: COMPARATOR
Intervention: Super evening primrose oil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 43
Study: 3663884

Group type: EXPERIMENTAL
Intervention: Single dose administration of quinidine gluconate and procainamide hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple dose administration of quinidine gluconate and procainamide hydrochloride
Number of subjects: 0
Study: 28540562

Group type: EXPERIMENTAL
Intervention: Home-based oral fluid rapid HIV self-testing
Number of subjects: 425

Group type: COMPARATOR
Intervention: Mail-in blood sample collection HIV test
Number of subjects: 425

Group type: COMPARATOR
Intervention: Medical facility/community organization-based HIV testing
Number of subjects: 425
Study: 26252950

Group type: EXPERIMENTAL
Intervention: Rikkunshito for 8 weeks
Number of subjects: 125
Study: 25070393

Group type: EXPERIMENTAL
Intervention: CyClean
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MeniCare
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ReNu
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (blister pack solution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Regard
Number of subjects: 30
Study: 23127342

Group type: EXPERIMENTAL
Intervention: Inhaled Salmeterol/fluticasone (SF) delivered by a metered-dose inhaler with a spacer
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inhaled nebulized ipratropium/terbutaline/budesonide (ITB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled Salmeterol/fluticasone (SF)
Number of subjects: 19
Study: 20223394

Group type: EXPERIMENTAL
Intervention: Long-axis approach
Number of subjects: 39

Group type: COMPARATOR
Intervention: Short-axis approach
Number of subjects: 39
Study: 18515448

Group type: EXPERIMENTAL
Intervention: 3-day taper
Number of subjects: 28

Group type: COMPARATOR
Intervention: 14-day taper
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: short half-life antidepressants
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: paroxetine
Number of subjects: 28
Study: 15733932

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5-HTP; 4 mg/kg in non enteric-coated tablets)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (20 matched healthy volunteers)
Number of subjects: 18
Study: 12837810

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (GemVin)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Cisplatin-based regimens (gemcitabine plus cisplatin or vinorelbine plus cisplatin)
Number of subjects: 501
Study: 10349695

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2b (rIFN-alpha 2b) plus oral ribavirin (1,000 or 1,200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant interferon alfa-2b (rIFN-alpha 2b) monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups (rIFN-alpha 2b alone and combination therapy)
Number of subjects: 0
Study: 7503040

Group type: EXPERIMENTAL
Intervention: Electrothermal debonding (ETD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional debonding method (pliers)
Number of subjects: 10
Study: 1772105

Group type: EXPERIMENTAL
Intervention: RU41740 (2 mg daily for one week in the first month, 1 mg daily for one week in the second month)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7075104

Group type: COMPARATOR
Intervention: 0.2 mg Digoxin + Placebo (PL2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.2 mg Digoxin + Quinidine (Q)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.4 mg Digoxin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.2 mg Digoxin + Sparteine (SP)
Number of subjects: 6
Study: 30790694

Group type: EXPERIMENTAL
Intervention: AED applied
Number of subjects: 2809

Group type: COMPARATOR
Intervention: No AED applied
Number of subjects: 2809
Study: 26053465

Group type: EXPERIMENTAL
Intervention: LNG-IUS inserted at the time of CS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (LNG-IUS inserted at six weeks postpartum)
Number of subjects: 48
Study: 24863486

Group type: EXPERIMENTAL
Intervention: PsA-TT vaccine (Meningococcal group A polysaccharide conjugated to tetanus toxoid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mencevax ACWY (quadrivalent plain polysaccharide vaccine)
Number of subjects: 0
Study: 22277697

Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 2% lignocaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: 18% benzocaine/2% tetracaine gel
Number of subjects: 32
Study: 18326529

Group type: EXPERIMENTAL
Intervention: Errorless learning (EL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional instruction (CI)
Number of subjects: 40
Study: 17329509

Group type: EXPERIMENTAL
Intervention: 0.87 g/d E2 gel
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: 1.7 g/d E2 gel
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: 2.6 g/d E2 gel
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 442
Study: 15215483

Group type: EXPERIMENTAL
Intervention: Folate therapy (1 mg of folic acid, 5 mg of vitamin B6, and 1 mg of vitamin B12 intravenously, followed by daily oral doses of 1.2 mg of folic acid, 48 mg of vitamin B6, and 60 microg of vitamin B12 for six months)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Folate therapy
Number of subjects: 636
Study: 11862564

Group type: EXPERIMENTAL
Intervention: Prophylactic drainage
Number of subjects: 59

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 59
Study: 9509065

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg orally for 4 days at 1700 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7876491

Group type: EXPERIMENTAL
Intervention: Direct electrical nerve stimulation
Number of subjects: 24
Study: 3177433

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 150 unit/kg intravenously three times weekly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 50 unit/kg intravenously three times weekly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 100 unit/kg intravenously three times weekly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (open label)
Number of subjects: 12
Study: 31693077

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dupilumab (both regimens)
Number of subjects: 251
Study: 28329863

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle redesign intervention (n = 232)
Number of subjects: 460

Group type: COMPARATOR
Intervention: No-treatment control (n = 228)
Number of subjects: 460
Study: 27573325

Group type: EXPERIMENTAL
Intervention: i-SIDRA
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional teaching methodology
Number of subjects: 200
Study: 24388167

Group type: EXPERIMENTAL
Intervention: Dinaciclib (IV, 50 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib (oral, 150 mg)
Number of subjects: 0
Study: 22486141

Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg tablets twice a day for one week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (tablets with the same dosage as sildenafil)
Number of subjects: 40
Study: 20398487

Group type: EXPERIMENTAL
Intervention: National-made ablation catheter (Group 1)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Imported ablation catheter (Group 2)
Number of subjects: 1342
Study: 18841079

Group type: EXPERIMENTAL
Intervention: Power scheme (8 sets of 6 repetitions at 45% of 1RM, 3-minute rest periods, explosive and ballistic movements)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypertrophy scheme (10 sets of 10 repetitions at 75% of 1RM, 2-minute rest periods, controlled movements)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maximal strength scheme (6 sets of 4 repetitions at 88% of 1RM, 4-minute rest periods, explosive intent)
Number of subjects: 11
Study: 16085339

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid total-tau (tau)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid phosphorylated-tau181 (p-tau181)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tau/Abeta42 ratio
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid phospho-tau(181)/Abeta42 ratio
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tau
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid p-tau(181)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid p-tau181
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid p-tau181/Abeta42 ratio
Number of subjects: 219
Study: 12678357

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mosaicplasty
Number of subjects: 100
Study: 10640840

Group type: EXPERIMENTAL
Intervention: 1% 5-fluorouracil in Belanyx vehicle
Number of subjects: 57

Group type: COMPARATOR
Intervention: Belanyx vehicle
Number of subjects: 57
Study: 8917247

Group type: EXPERIMENTAL
Intervention: Clarithromycin, 10 mg/kg per day, twice a day for 7 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Azithromycin, 10 mg/kg per day, once a day for 5 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Erythromycin (historical control)
Number of subjects: 17
Study: 1899732

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid treatment (0.5 g solumedrol) before or at the same time as the first OKT3 injection
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid treatment (0.5 g solumedrol) before the first OKT3 injection
Number of subjects: 27
Study: 7040581

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg oral dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diltiazem 240 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30889566

Group type: EXPERIMENTAL
Intervention: Essential Tremor (ET) prevalence assessment
Number of subjects: 1328
Study: 30541152

Group type: EXPERIMENTAL
Intervention: Portal use education
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 26716866

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg kg(‐1) loading dose over 10 min followed by 0.5 μg kg(‐1) h(‐1) during one-lung ventilation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 50
Study: 25325116

Group type: EXPERIMENTAL
Intervention: Aflibercept added to Folfiri protocol
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 1226
Study: 22627919

Group type: EXPERIMENTAL
Intervention: Lower abdomen
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Upper abdomen
Number of subjects: 4
Study: 20226443

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplementation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (age-matched women)
Number of subjects: 56
Study: 17635426

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 100

Group type: COMPARATOR
Intervention: Facemask and oropharyngeal airway
Number of subjects: 100

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 100